Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


A simple algorithm with one flow cytometric MRD measurement identifies more than 40% of children with ALL who can be cured with low-intensity therapy. The ALL-MB 2008 trial results

Your institute does not have access to this article

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Event-free survival (EFS, solid lines) and cumulative incidence of relapse (CIR, dashed lines) according to MFC-MRD values.

Data availability

For original data, please contact


  1. Inaba H, Pui CH. Advances in the diagnosis and treatment of pediatric acute lymphoblastic leukemia. J Clin Med. 2021;10:1926.

  2. Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373:1541–52.

    CAS  Article  Google Scholar 

  3. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, et al. Chronic health conditions in adult survivors of childhood cancer. N. Engl J Med. 2006;355:1572–82.

    CAS  Article  Google Scholar 

  4. Yeh JM, Hanmer J, Ward ZJ, Leisenring WM, Armstrong GT, Hudson MM, et al. Chronic conditions and utility-based health-related quality of life in adult childhood cancer survivors. J Natl Cancer Inst. 2016;108:djw046.

  5. Basso G, Veltroni M, Valsecchi MG, Dworzak MN, Ratei R, Silvestri D, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol. 2009;27:5168–74.

    Article  Google Scholar 

  6. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood 2008;111:5477–85.

    CAS  Article  Google Scholar 

  7. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grumayer R, Moricke A, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010;115:3206–14.

    CAS  Article  Google Scholar 

  8. Pui CH, Pei D, Coustan-Smith E, Jeha S, Cheng C, Bowman WP, et al. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncol. 2015;16:465–74.

    Article  Google Scholar 

  9. Popov A, Belevtsev M, Boyakova E, Verzhbitskaya T, Movchan L, Fadeeva M, et al. Standardization of flow cytometric minimal residual disease monitoring in children with B-cell precursor acute lymphoblastic leukemia. Russia–Belarus multicenter group experience. Oncohematology. 2016;11:64–73.

    Article  Google Scholar 

  10. Maurer-Granofszky M, Schumich A, Buldini B, Gaipa G, Kappelmayer J, Mejstrikova E, et al. An extensive quality control and quality assurance (QC/QA) program significantly improves inter-laboratory concordance rates of flow-cytometric minimal residual disease assessment in acute lymphoblastic leukemia: an I-BFM-FLOW-Network report. Cancers. 2021;13:6148.

  11. Gupta S, Devidas M, Loh ML, Raetz EA, Chen S, Wang C, et al. Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children’s Oncology Group (COG). Leukemia. 2018;32:1370–9.

    Article  Google Scholar 

  12. Dworzak MN, Froschl G, Printz D, Mann G, Potschger U, Muhlegger N, et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood. 2002;99:1952–8.

    CAS  Article  Google Scholar 

  13. Pedrosa F, Coustan-Smith E, Zhou Y, Cheng C, Pedrosa A, Lins MM, et al. Reduced-dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study. Blood. 2020;135:1458–66.

    Article  Google Scholar 

  14. Sidhom I, Shaaban K, Youssef SH, Ali N, Gohar S, Rashed WM, et al. Reduced-intensity therapy for pediatric lymphoblastic leukemia: impact of residual disease early in remission induction. Blood. 2021;137:20–8.

    CAS  Article  Google Scholar 

  15. Pieters R, de Groot-Kruseman H, Van der Velden V, Fiocco M, van den Berg H, de Bont E, et al. Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch childhood oncology group. J Clin Oncol. 2016;34:2591–601.

    Article  Google Scholar 

  16. Schrappe M, Bleckmann K, Zimmermann M, Biondi A, Moricke A, Locatelli F, et al. Reduced-intensity delayed intensification in standard-risk pediatric acute lymphoblastic leukemia defined by undetectable minimal residual disease: results of an international randomized trial (AIEOP-BFM ALL 2000). J Clin Oncol. 2018;36:244–53.

    CAS  Article  Google Scholar 

  17. Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013;14:199–209.

    CAS  Article  Google Scholar 

Download references


The authors thank all doctors, nurses and laboratory personel in participating institutions, who were involved in patients diagnostics, management and monitoring. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations



AP – concept and design of the study, MFC-MRD data, data analysis and interpretation, writing the paper. GH – concept and design of the study, data analysis and interpretation, writing the paper. JR – database handling, data analysis and interpretation, writing the paper. OB – database handling, statistics. MB – MFC-MRD data. TV – MFC-MRD data. EB – MFC-MRD data. LM – MFC-MRD data. GT – data analysis and interpretation. MF – MFC-MRD data. SL – database handling, data analysis. LZh – database handling, data analysis. NM – patients data. DL – patients data. OKh – patients data. OS – patients data. ES – patients data. NP – patients data. GN – concept and design of the study, general supervising, writing the paper. LF – concept and design of the study, general supervising, writing the paper. OA – concept and design of the study, general supervising, writing the paper. AK – concept and design of the study, data analysis and interpretation, general supervising, writing the paper. AP and GH contributed equally to this work. All authors have read and approved the final version of manuscript.

Corresponding author

Correspondence to Alexander Popov.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Popov, A., Henze, G., Roumiantseva, J. et al. A simple algorithm with one flow cytometric MRD measurement identifies more than 40% of children with ALL who can be cured with low-intensity therapy. The ALL-MB 2008 trial results. Leukemia 36, 1382–1385 (2022).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


Quick links